Press Releases

Biophytis Publishes First-Half Financial Results and Provides an Update on its Business Activities Biophytis publishes its financial results for the first half of 2024 and provides an update on the company’s key achievements. Stanislas Veillet, CEO of Biophytis, commented: “We are particularly pleased with the progress made in the first half of 2024. The launch of our clinical program OBA for obesity, addressing a major public health issue, and our partnership with Blanver to develop BIO101 in Latin America, are key milestones that demonstrate Biophytis’ ability to innovate and capitalize on market opportunities. We are now entering a critical phase

Biophytis obtains IND approval from the FDA to start its phase 2 OBA study in obesity Biophytis announced that it has received Investigational New Drug (IND) approval from the Food and Drug Administration (FDA) for its phase 2 OBA clinical study in obesity with BIO101 (20-hydroxyecdysone). The primary objective of the study is to measure the improvement in muscle strength in the lower limbs, as assessed by knee extension test. Secondary endpoints will include analysis of mobility (via the 6-minute walk test) and body composition (assessment of fat and lean mass). A world-renowned medical expert in the field of obesity

Biophytis presented its Phase 2-3 COVA study results in severe forms of Covid-19 at the WCID in Paris Biophytis presented the roll-out and results of its phase 2/3 COVA study in the treatment of severe forms of Covid-19 at the 6th edition of the World Congress on Infectious Diseases, held from June 24 to 26, 2024 in Paris, France. Professor Valerie Pourcher MD, PhD, Chaiman of the Infectious Diseases department at Pitié Salpetriere, presented the COVA phase 2/3 clincial study results in a context where the number of Covid cases rises again. Dr. Claudia Ferreira MD, PhD, Medical Director at

RESULTS OF THE COMBINED GENERAL MEETING ON JUNE 24, 2024 All resolutions presented by the Company have been adopted Biophytis announces the approval of all the resolutions presented by the Company and falling within the remit of the Ordinary and Extraordinary General Meeting. Thanks to the mobilization of shareholders, the Meeting could be held with a quorum of almost 34% of the shareholders present or represented. The resolutions notably included the approval of the financial statements fo the fiscal year 2023 and the renewal for three years of Stanislas Veillet, Nadine Coulm and Claude Allary as Directors. The results of

Biophytis announces the successful industrial transfer of BIO101 (20-hydroxyecdysone) production by its service provider Seqens Seqens, an integrated global player in solutions and ingredients for the pharmaceutical and speciality markets, offering a broad portfolio of active ingredients, pharmaceutical intermediates and speciality products, has produced the first GMP-compliant batch of BIO101 (20-hydroxyecdysone) at its plant in Villeneuve La Garenne (Île-de-France). This batch is now available for use in Biophytis’ clinical development programme to treat respiratory deterioration in patients with Duchenne Muscular Dystrophy (DMD). DMD is a rare genetic disease that causes severe and progressive muscle degeneration, mainly affecting boys. BIO101 (20-hydroxyecdysone)

Biophytis announces filing of an IND application with the US FDA for its phase 2 study in obesity Biophytis announces that it has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) regarding its phase 2 OBA clinical study in obesity with BIO101 (20-hydroxyecdysone). Fullscreen Mode